Using gene-specific radiolabeled probe DNAs, we analyzed 42 clinical bacterial isolates with high-level trimethoprim (Tp) resistance for the presence of a type I or a type II plasmid-specified dihydrofolate reductase (DHFR) gene. Plasmid DNA from 17 strains harbored a type I DHFR, whereas 11 isolates contained plasmids that harbored a type II DHFR structural gene. The plasmid DNAs from five strains appeared to hybridize with both type I and type II DHFR probe DNAs. In addition, eight isolates had type I resistance determinants integrated into the chromosomes, presumably on transposon 7 (Tn7). Among the strains analyzed in this survey, none of the chromosomally located, Tp-insensitive reductases were of the type II class. Both the plasmid and chromosomal DNAs of one isolate showed no homology with either the type I or type II DHFR probe DNA. The plasmid harbored by this strain encoded a "new" Tp-resistant enzyme that differed significantly, both in molecular weight and with respect to trimethoprim and methotrexate inhibition kinetics, from the previously characterized plasmidassociated dihydrofolate reductases. R plasmid-mediated trimethoprim (Tp) resistance has been recognized since 1971 (14). The mechanism of plasmid-associated Tp resistance is unusual in that the R plasmids harbor the structural genes for dihydrofolate reductases (DHFRs), which are highly resistant to trimethoprim; hence, the target site rather than the antimicrobial agent is modified (4, 25).
Using gene-specific radiolabeled probe DNAs, we analyzed 42 clinical bacterial isolates with high-level trimethoprim (Tp) resistance for the presence of a type I or a type II plasmid-specified dihydrofolate reductase (DHFR) gene. Plasmid DNA from 17 strains harbored a type I DHFR, whereas 11 isolates contained plasmids that harbored a type II DHFR structural gene. The plasmid DNAs from five strains appeared to hybridize with both type I and type II DHFR probe DNAs. In addition, eight isolates had type I resistance determinants integrated into the chromosomes, presumably on transposon 7 (Tn7). Among the strains analyzed in this survey, none of the chromosomally located, Tp-insensitive reductases were of the type II class. Both the plasmid and chromosomal DNAs of one isolate showed no homology with either the type I or type II DHFR probe DNA. The plasmid harbored by this strain encoded a "new" Tp-resistant enzyme that differed significantly, both in molecular weight and with respect to trimethoprim and methotrexate inhibition kinetics, from the previously characterized plasmidassociated dihydrofolate reductases.
R plasmid-mediated trimethoprim (Tp) resistance has been recognized since 1971 (14) . The mechanism of plasmid-associated Tp resistance is unusual in that the R plasmids harbor the structural genes for dihydrofolate reductases (DHFRs), which are highly resistant to trimethoprim; hence, the target site rather than the antimicrobial agent is modified (4, 25) .
Plasmid-specified DHFRs can be arbitrarily divided into two broad categories based on different levels of sensitivity to Tp and other related antifolate compounds (23) . Type I reductases have 50% inhibitory concentrations for trimethoprim several thousand-fold higher than that required to inhibit the Escherichia coli chromosomal DHFR. So-called type II DHFRs are, for all practical purposes, insensitive to Tp, having 50% inhibitory concentrations several hundred-fold higher than those for the type I reductases. Several of these plasmid-encoded enzymes have been reasonably well characterized. It is known, for example, that the type I DHFF1 specified by plasmid R483 (11) and the type II enzyme encoded by plasmid R67 are very different enzymes; they differ antigenically and in subunit structure (15) . Furthermore, preliminary evidence suggests they are unrelated at the level of their nucleotide base sequence (D. Stone, personal communication).
In most parts of the world, the proportion of pathogens sensitive to trimethoprim has remained high, despite increased usage of trimethoprim-sulfonamide combinations over the past 12 years (2). However, there is cause for concern that this resistance picture is changing. For example, Datta et al. (12) 
MATERIALS AND METHODS
Bacterial strains and plasmids. The clinical isolates used in this study are described in Table 1 . E. coli K-12, C-600 and E. coli B, HB101 were also used (6) . The recombinant plasmid pFE364 was constructed by inserting a 2.5-kilobase (kb) BamHI-EcoRI fragment of plasmid R67 into pBR322 (10) (10) .
Plasmid DNA extraction and gel electrophoresis. Cultures were inoculated in 0.5 to 1.0 ml of MuellerHinton broth and grown overnight in Eppendorf tubes. The alkaline extraction method of Bimboim and Doly (9) (Fig. 2) . Seven of the 12 radiolabeled type II DHFR probe. The remaining five DNAs showed no nucleotide sequence homology with this particular probe. The faint, common band (Fig. 2, arrow) is RNA. When samples were treated with RNase before electrophoresis, this band disappeared. Figure 3 shows the results of a similar experiment in which a gel blot was probed with the 32p_ labeled DNA fragment containing the type I DHFR structural gene. Restricted plasmid DNAs that showed sequence homology with the type II DHFR probe (Fig. 2 ) did not react with radiolabeled type I probe DNA (e.g., P258, P259, P193, P570, P626, and P237). Conversely, strains whose restricted plasmid DNAs did not react with the type II DHFR DNA probe hybridized strongly with the radiolabeled type I DHFR DNA probe (e.g., P195, P629, P42, P590, and P759), indicating the high degree of specificity of the gene probes. (30) reported that these strains synthesize an additional, Tp-insensitive reductase with an inhibitory profile similar to that of a plasmid-specified type I DHFR. Representative colonies of each of the nine "double-negative" strains were lysed on nitrocellulose filters, and the resultant whole cell DNA imprints were probed with 32P-labeled plasmid pFE506. This derivative plasmid contains the structural gene for the type I DHFR harbored by Tn7 (8) . The whole cell DNA from four of these Tp-resistant, "double-negative" isolates (P62-P65) hybridized with the type I DHFR probe (Fig. 4) . A positive control strain (P195) gave an expected positive reaction. On the other hand, no reaction was observed between this probe and DNA extracted from a plasmid-free, Tp-sensitive strain (F-) or an isolate harboring the structural gene for a type II DHFR (P100). Since plasmid pFE506 contains a fragment of ColEl (10), a colony hybridization experiment was carried out, using 32P-labeled ColEl as a probe. None of the DNA imprints hybridized with radiolabeled ColEl (data not shown). These results suggest that Tn7, or at least a portion of Tn7 containing the structural gene for DHFR, has become integrated into the chromosome of these Tp-resistant strains. An alternative interpretation is that these isolates harbor a second, presumably larger, plasmid that is going undetected with the lysis conditions employed in this study. We consider this possibility to be extremely unlikely.
Restricted plasmid DNA from five resistant strains (Table 2) mid. In the case of the other four strains, another explanation is more likely. The type I DHFR probe originally used in these experiments contained a 4-kb segment of Tn7 which included at least a portion of the gene specifying a streptomycin-inactivating enzyme. Therefore, the potential for cross-hybridization with non-DHFR genes is inherently greater with the type I probe compared with the type II DHFR probe. However, this ambiguity was a problem in only five (9.5%) of the isolates examined in this survey.
One of us (M.F.) has constructed a type I probe consisting of a 1.0-kb TaqI fragment from plasmid R483. Our preliminary results show that plasmid DNA fragments from most of the "double-positive" strains do not react, or hybridize only weakly, with this smaller type I DHFR probe.
Detection of a "new" plasmid-specified DHFR. In the course of this survey, we encountered one Tp-resistant isolate (P669, Table 1 ) that was especially intriguing. This E. coli K-12 transconjugant harbored an 8-kb plasmid that conferred resistance to trimethoprim and sulfonamide (1). The donor was a strain of Salmonella typhimurium phage type 179, an organism implicated in epidemics in cattle and sporadic human infections in Great Britain (2, 34) . The Salmonella donor strain contained two R plasmids: a 90-kb plasmid conferring ampicillin and tetracycline resistance and an 8-kb trimethoprim and sulfonamide resistance plasmid (1). This particular E. coli transconjugant (strain P669) harbored only the 8-kb plasmid. It was presumably mobilized from the donor by the 90-kb plasmid, which was subsequently eliminated from the recipient strain. Of further interest was the fact that the minimal inhibitory concentration (MIC) for trimethoprim in both the S. typhimurium and E. coli hosts that harbored this particular plasmid was 64 pug/ml. This is quite low compared with that of transferable Tp resistance previously observed, in which the MIC for trimethoprim was 1,000 to 2,000 ,ug/ml (23) . Furthermore, restricted plasmid DNA isolated from the E. coli transconjugant strain P669 did not hybridize with the radiolabeled type I DHFR DNA probe (Fig. 3) , nor did it react with the type II DHFR probe (data not shown). The possibility that either a type I or a type II Tp-resistant reductase gene had become incorporated into the chromosome of this strain was ruled out by the fact that colony hybridization experiments, using both radiolabeled DNA probes, were clearly negative (this was the only strain of nine "double-negative" isolates that did not react in the colony hybridization experiment).
The plasmid-specified reductase of this strain has been partially characterized (D. Baccanari, personal communication). It appears to be significantly different from both of the previously described plasmid-specified DHFR classes (23) . For example, its molecular weight is 16,000 to 18,000, compared with a molecular weight of 34,000 to 36,000 for both the type I and type II reductases. The trimethoprim 50% inhibitory concentration for this "new" DHFR is approximately 1.5 ance is increasing, especially in the hospital environment (4, 32) . The need to closely monitor developing trends in bacterial susceptibility to trimethoprim, as well as to other antimicrobial agents, is an obvious one.
Using the sequence of techniques outlined in this study, we screened 42 naturally occurring bacterial strains with high-level Tp resistance for the presence of either type I or type II plasmidencoded reductase genes. The plasmid DNAs of 17 strains (40.5%) contained the structural gene for a type I reductase, whereas the chromosomal DNAs of eight isolates (19%) appeared to harbor the type I gene determinant. The predominance of the type I DHFR gene among these isolates (59.5% of the total analyzed, if the strains with type I DHFR determinants integrated into the chromosomes are included) can perhaps be explained by the fact that this determinant resides on a transposon, Tn7. The fact that almost onefifth of the strains analyzed in this survey contained type I plasmid-encoded DHFR genes integrated into their chromosomes supports the recent report of a significant increase in the isolation frequency of clinical strains with highlevel, nontransferable trimethoprim resistance (31) . This is a potentially disquieting trend since this resistance is inherently more stable than plasmid-mediated resistance and not likely to be lost once the selective pressure is removed.
Lichtenstein and Brenner (19) 256Fxg/ml) compared with the level of resistance usually associated with R plasmids (MIC greater than 1 mg/ml). These authors speculated that this R plasmid specified an "intermediate" type of DHFR more sensitive to trimethoprim than the "normal" plasmid-encoded reductases. The enzyme specified by plasmid pUN212 was not characterized. We found and partially characterized such an "intermediate" plasmid-specified DHFR originating in a multiply drug-resistant S. typhimurium strain isolated by Anderson in New Zealand (1). This unusual reductase differs significantly from its plasmid-associated predecessor DHFRs in molecular weight and inhibition profile (Tp resistant and yet methotrexate sensitive), as well as the relatively low level of trimethoprim resistance it confers upon its host bacterium (64 ,ug/ml). This finding serves to deepen the mystery as to the origin of these resistance determinants (e.g., the amino acid sequence of the type II plasmid-encoded DHFR bears no sequence homology with any other characterized reductase: bacterial, phage, or mammalian) and suggests that these plasmidspecified enzymes comprise a rather heterogeneous group.
